Maricer P. Escalón

977 total citations
22 papers, 724 citations indexed

About

Maricer P. Escalón is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Maricer P. Escalón has authored 22 papers receiving a total of 724 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 7 papers in Hematology. Recurrent topics in Maricer P. Escalón's work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (5 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Maricer P. Escalón is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (5 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Maricer P. Escalón collaborates with scholars based in United States, United Kingdom and Australia. Maricer P. Escalón's co-authors include Izidore S. Lossos, Terry L. Smith, Ying Yang, A. N. Serafini, Pamela L. Walker, Nam H. Dang, Hyo S. Han, Mark A. Hess, Denise Pereira and Issa F. Khouri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Maricer P. Escalón

19 papers receiving 709 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maricer P. Escalón United States 12 408 263 208 200 117 22 724
Julien Lazarovici France 10 335 0.8× 435 1.7× 189 0.9× 112 0.6× 94 0.8× 36 684
José R. Valbuena United States 18 357 0.9× 204 0.8× 128 0.6× 185 0.9× 182 1.6× 41 809
Gregory Bociek United States 14 562 1.4× 379 1.4× 131 0.6× 129 0.6× 230 2.0× 35 836
Francesco Gaudio Italy 13 349 0.9× 270 1.0× 204 1.0× 201 1.0× 112 1.0× 53 676
Hirotaka Takasaki Japan 16 317 0.8× 244 0.9× 131 0.6× 153 0.8× 148 1.3× 59 732
Christina Kalpadakis Greece 17 413 1.0× 235 0.9× 107 0.5× 177 0.9× 311 2.7× 48 727
Dimitra Anagnostou Greece 16 303 0.7× 169 0.6× 132 0.6× 188 0.9× 251 2.1× 41 700
Alfonso Maria D’Arco Italy 13 358 0.9× 264 1.0× 107 0.5× 269 1.3× 248 2.1× 27 819
Birgit Federmann Germany 15 343 0.8× 298 1.1× 284 1.4× 329 1.6× 198 1.7× 45 788
Atto Billio Italy 15 328 0.8× 209 0.8× 345 1.7× 331 1.7× 257 2.2× 37 840

Countries citing papers authored by Maricer P. Escalón

Since Specialization
Citations

This map shows the geographic impact of Maricer P. Escalón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maricer P. Escalón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maricer P. Escalón more than expected).

Fields of papers citing papers by Maricer P. Escalón

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maricer P. Escalón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maricer P. Escalón. The network helps show where Maricer P. Escalón may publish in the future.

Co-authorship network of co-authors of Maricer P. Escalón

This figure shows the co-authorship network connecting the top 25 collaborators of Maricer P. Escalón. A scholar is included among the top collaborators of Maricer P. Escalón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maricer P. Escalón. Maricer P. Escalón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bruno, Débora S., et al.. (2024). Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USA. Acta Haematologica. 148(2). 1–15.
2.
Woyach, Jennifer A., et al.. (2023). BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.. Journal of Clinical Oncology. 41(16_suppl). TPS7584–TPS7584. 1 indexed citations
3.
Woyach, Jennifer A., William G. Wierda, Catherine C. Coombs, et al.. (2022). BRUIN CLL-314: A Phase III Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood. 140(Supplement 1). 12427–12428. 5 indexed citations
4.
Bayraktar, Soley & Maricer P. Escalón. (2011). Secondary hematological malignancies following breast cancer treatment. SHILAP Revista de lepidopterología. 4(1). 51–51.
5.
Escalón, Maricer P. & Krishna V. Komanduri. (2010). Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. Current Opinion in Oncology. 22(2). 122–129. 25 indexed citations
6.
Ribeiro, Afonso, Denise Pereira, Maricer P. Escalón, Mark M. Goodman, & Gerald E. Byrne. (2010). EUS-guided biopsy for the diagnosis and classification of lymphoma. Gastrointestinal Endoscopy. 71(4). 851–855. 48 indexed citations
7.
Escalón, Maricer P., et al.. (2010). Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Reports. 2010. bcr0520102975–bcr0520102975. 15 indexed citations
8.
Bayraktar, Soley & Maricer P. Escalón. (2010). Secondary hematological malignancies following breast cancer treatment. Oncology Reviews. 4(1). 51–59.
9.
10.
Escalón, Maricer P., Alexandra Stefanovic, Denise Pereira, et al.. (2009). Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplantation. 44(2). 89–96. 11 indexed citations
11.
12.
13.
Escalón, Maricer P. & Izidore S. Lossos. (2008). Pharmacotherapy of large B-cell lymphoma. Expert Opinion on Pharmacotherapy. 9(13). 2247–2258. 8 indexed citations
14.
Hosein, Peter J., Daniel Morgensztern, Gail Walker, et al.. (2008). High Remission Rates and Prolonged Progression Free Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma Treated with R-MACLOIVAM-T. Blood. 112(11). 3597–3597. 2 indexed citations
15.
Bayraktar, Ulas D. & Maricer P. Escalón. (2008). An Unusual Presentation of Acute Biphenotypic Leukemia without Bone Marrow Involvement. Blood. 112(11). 3995–3995. 1 indexed citations
16.
Fernández, Hugo F., Maricer P. Escalón, Denise Pereira, & Hillard M. Lazarus. (2007). Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplantation. 40(6). 505–513. 35 indexed citations
17.
Lossos, Izidore S., et al.. (2007). Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma.. Blood. 110(11). 1363–1363. 2 indexed citations
18.
Han, Hyo S., Maricer P. Escalón, Aldo N. Serafini, & Izidore S. Lossos. (2006). High Incidence of False Positive PET Scans in Patients with Aggressive Non-Hodgkins Lymphoma Treated with Rituximab-Containing Regimens.. Blood. 108(11). 2401–2401. 1 indexed citations
19.
Escalón, Maricer P., Ying Yang, Mark A. Hess, et al.. (2005). Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma. Cancer. 103(10). 2091–2098. 169 indexed citations
20.
Couriel, Daniel R., Rima M. Saliba, Maricer P. Escalón, et al.. (2005). Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft‐versus‐host disease. British Journal of Haematology. 130(3). 409–417. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julien Lazarovici Breakdown of academic impact, for papers by José R. Valbuena Breakdown of academic impact, for papers by Gregory Bociek Breakdown of academic impact, for papers by Francesco Gaudio Breakdown of academic impact, for papers by Hirotaka Takasaki Breakdown of academic impact, for papers by Christina Kalpadakis Breakdown of academic impact, for papers by Dimitra Anagnostou Breakdown of academic impact, for papers by Alfonso Maria D’Arco Breakdown of academic impact, for papers by Birgit Federmann Breakdown of academic impact, for papers by Atto Billio
Rankless by CCL
2026